Cargando…
Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients
BACKGROUND: The antiviral agent favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. MATERIALS AND METHODS: We examined patients with a clinical, laboratory, and radiological diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the effect of administering en...
Autores principales: | Karatas, Ercan, Aksoy, Lacin, Ozaslan, Ersin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258292/ https://www.ncbi.nlm.nih.gov/pubmed/34216123 http://dx.doi.org/10.3947/ic.2020.0149 |
Ejemplares similares
-
An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022) -
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021) -
Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
por: Fujii, Satoshi, et al.
Publicado: (2021) -
Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022) -
Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
por: Tatar, Erhan, et al.
Publicado: (2020)